![Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials - The Lancet Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials - The Lancet](https://www.thelancet.com/cms/attachment/a6e04134-5021-4c69-8936-add20f5e935d/gr1.gif)
Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials - The Lancet
![Table 1 from Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial. | Semantic Scholar Table 1 from Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8b80fdb62e5d1cdfe535f83c7d0d827c0115441e/2-Table1-1.png)
Table 1 from Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial. | Semantic Scholar
![IJMS | Free Full-Text | 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs? IJMS | Free Full-Text | 40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?](https://www.mdpi.com/ijms/ijms-23-03431/article_deploy/html/images/ijms-23-03431-g001.png)